LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.
“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”
Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”
According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
LG Chem Life Sciences Innovation Center: innovation.lgchem.com
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005934/en/
Contact information
Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIKE, Inc. Announces Senior Leadership Changes to Accelerate “Win Now” Actions2.12.2025 23:59:00 EET | Press release
NIKE, Inc. (NYSE:NKE) today shared the following note with employees regarding changes to its Senior Leadership Team. // Team, I’d like to share some important changes to our Senior Leadership Team (SLT) that further remove layers and continue to bring us closer to athletes* and the marketplace. We’re establishing the role of EVP, Chief Operating Officer (COO), reporting to me, to better connect our operations and integrate technology more seamlessly into our sport offense. Venkatesh Alagirisamy (“Venky”), currently Chief Supply Chain Officer and a nearly 20-year Nike veteran, will take on this role effective December 8. Venky will lead Technology, in addition to his existing responsibilities leading Supply Chain, Planning, Operations, Manufacturing and Sustainability. He and his team will now be able to look end-to-end to ensure technology is fully integrated across the company and into how we create, plan, make, deliver and sell our world-class innovations across our three iconic bra
NetApp Collaborates with AWS to bring Enterprise Data to AWS AI Services2.12.2025 20:30:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a new capability that enables enterprises to make their workflows simpler and more efficient by connecting Amazon Web Services (AWS) AI and Analytics services directly with their NetApp data both in the cloud and on-premises. Amazon S3 Access Points for Amazon FSx for NetApp ONTAP® enable customers to accelerate AI and analytics projects by allowing FSx for ONTAP-resident file data to be accessed via the S3 API by AWS's extensive portfolio of AI/ML and analytics services—all while the data remains in place and is fully accessible for read / write via file protocols. “By connecting FSx for ONTAP data natively to AWS's wide range of AI, ML, and analytics services, the new integration with Amazon S3 Access Points unleashes the potential to connect to more than 100 exabytes of enterprise data stored on NetApp systems for transformative use cases like generative AI and analytics uses cases built on AWS,” sa
SLB Announces Dates for Fourth-Quarter and Full-Year 2025 Results Conference Call2.12.2025 20:00:00 EET | Press release
SLB (NYSE: SLB) will hold a conference call on January 23, 2026, to discuss the results for the fourth quarter and full year ending December 31, 2025. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (646) 844-6383 outside of North America approximately 10 minutes prior to the start of the call and the access code is 122785. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/391273915 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until January 30, 2026, and can be accessed by dialing +1 (866) 813-9403 within North
Daikin Leverages DataXstream’s OMS+ to Take Customer Experience to New Heights2.12.2025 17:03:00 EET | Press release
DataXstream LLC, an SAP® Endorsed App partner developing intelligent solutions for SAP sales and distribution, announced today that Daikin Comfort Technologies North America, Inc. (Daikin), a subsidiary of Daikin Industries Ltd. and leading HVAC manufacturer, has selected its OMS+ platform to deliver real-time point-of-sales capabilities, along with an intuitive, streamlined order management to transform Daikin’s in-store and online customer experience. Leveraging SAP solutions, Daikin and DataXstream are elevating the way customers engage with Daikin’s stores and brand by delivering unparalleled, consistent point-of-sale capabilities, along with real-time visibility of orders and inventory across all sales channels. “Customers want a consistent and responsive experience, regardless of where they place their order,“ said Tim Yates, CEO, DataXstream. “But no channel exists in a vacuum. To provide that level of consistency you need a platform that can view and aggregate data in real-time
Halo Infinite and Elysium Senior Concept Designer Ben Mauro Launches HUXLEY: The Oracle - Sci-Fi Prequel Debuts as #1 Amazon New Release2.12.2025 17:00:00 EET | Press release
Ben Mauro, the acclaimed concept artist and worldbuilder behind Halo Infinite, Call of Duty, Elysium, and The Predator, today announced the US release of HUXLEY: The Oracle. The book, serving as the narrative prequel to Mauro’s expanding HUXLEY universe, has already reached #1 in Amazon’s New Releases for Conceptual Art based on pre-orders alone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202609807/en/ HUXLEY: The Oracle Cover illustration HUXLEY: The Oracle departs from the graphic novel format in the first book, adopting an immersive narrative art book format that pairs cinematic, full-page illustrations alongside storytelling. Using a format familiar to readers of Simon Stålenhag’s Tales from the Loop, the book places world-building at the forefront, delivering a large-scale, atmospheric introduction to the world of HUXLEY that is fitting to the new story. HUXLEY: The Oracle unites a "dream team" of industry heavyw
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom